Sanofi

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma S.a.

Antaros Medical Ab

Martin Bossart

Michael Wagner

Andreas Evers

Torsten Haack

Dieter Kadereit

Siegfried Stengelin

Katrin Lorenz

Karl Schoenafinger

Hans Matter

David William Will

Bernd Henkel

Swen Hoelder

Ralf Elvert

Pradeep K Dhal

James E Stefano

Thomas Olpp

Nino Meyer

Paul Konowicz

Guenter Mueller

Gunter Muller

Martin Lorenz

Anke Steinmetz

Stefania Pfeiffer-Marek

Ingrid Sassoon

Cecile Combeau

Didier Benard

Christine Delaisi

Nils Poth

Peyman Sakhaii

Heiner Glombik

Matthias Gossel

Lothar Schwink

Thomas Klabunde

Oliver Plettenburg

Thomas Maier

Marc Nazare

Werngard Czechtizky

Detlef Kozian

Aimo Kannt

Marc Nazaré

Robert Miller

Magnus Besev

Werner Seiz

Romain Bertrand

Maximilian Bielohuby

Stephanie Keil

The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.

GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L-L-L-L-Y&#x2014;Rgroups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.

Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L-L-L-Y&#x2014;R, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist. 

Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y&#x2014;R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), 

Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

Exendin-4 derivatives as dual GLP1/glucagon agonists

The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists

Compounds as peptidic GLP1/glucagon/GIP receptor agonists

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists

The present invention relates to dual GLP-1/glucagon receptor agonists or optionally trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4

Dual GLP-1/glucagon receptor agonists derived from exendin-4

Dual GLP-1/glucagon receptor agonists

The present invention relates to compounds of the formula (I), wherein the residues A, Rto R, Zand Zhave the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them. 

Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists

Growing community of inventors

Frankfurt am Main, Germany

Martin Bossart